Search Results

You are looking at 1 - 10 of 109 items for :

  • "androgen deprivation therapy" x
  • Refine by Access: All x
Clear All
Full access

Celestia S. Higano

Androgen deprivation therapy (ADT) has been the standard of care for metastatic prostate cancer since 1941, when Huggins and Hodges 1 demonstrated the effect of androgens on prostate cancer and the impact of orchiectomy on bone pain symptoms. Hot

Full access

Miren Gaztañaga and Juanita Crook

. Both trials closed prematurely but are in the follow-up period and will combine their data on more than 350 patients. Table 2 Summary of Level 1 Evidence for Androgen Deprivation Therapy in High-Risk Patients Once ADT has been initiated

Full access

Alice Dragomir, Nawar Touma, Jason Hu, Sylvie Perreault, and Armen G. Aprikian

, (E) IHD, and (F) aggregate CVD (any of 5 outcomes) with and without prior CVD, stratified by ADT type. Abbreviations: ADT, androgen deprivation therapy; CHF, chronic heart failure; CVD, cardiovascular disease; GnRH, gonadotropin-releasing hormone

Full access

Jason Hu, Armen G. Aprikian, Marie Vanhuyse, and Alice Dragomir

important aspect to consider. Androgen deprivation therapy (ADT) is a cornerstone of advanced PCa treatment, and it is estimated that nearly 1 in 2 patients with PCa will receive some form of ADT during their disease course. 3 , 4 The role of ADT is strongly

Full access

Brandon A. Mahal, Ming-Hui Chen, Andrew A. Renshaw, Marian J. Loffredo, Philip W. Kantoff, and Anthony V. D'Amico

the study cohort, stratified by PSA-DT and PSA level at the time of salvage ADT. PSA-DT Figure 1. CONSORT diagram. Abbreviations: 3D-CRT, 3D conformal radiation therapy; ADT, androgen deprivation therapy; LHRH, luteinizing hormone

Full access

Philip J. Saylor and Matthew R. Smith

/print certificate. Learning Objectives Upon completion of this activity, participants will be able to: • Identify clinical scenarios in which androgen deprivation therapy (ADT) is most useful in the treatment of prostate cancer • Describe

Full access

U-Syn Ha, Jin Bong Choi, Jung Im Shim, Minjoo Kang, Eunjung Park, Shinhee Kang, Jooyeon Park, Jangmi Yang, Insun Choi, Jeonghoon Ahn, Cheol Kwak, Chang Wook Jeong, Choung Soo Kim, Seok-Soo Byun, Seong Il Seo, Hyun Moo Lee, Seung-Ju Lee, Seung Hwan Lee, Byung Ha Chung, and Ji Youl Lee

Background Although major groups or guidelines do not recommend primary androgen deprivation therapy (PADT) as primary treatment of nonmetastatic prostate cancer, 1 , 2 a considerable number of physicians have used PADT for nonmetastatic prostate

Full access

James L. Mohler

The strategic application of androgen deprivation therapy (ADT) in the clinic is still evolving, according to James L. Mohler, MD, Chair of the Department of Urology and Associate Director of Translational Research, Roswell Park Cancer Institute

Full access

Dennis R. Taaffe, Robert U. Newton, Nigel Spry, David J. Joseph, and Daniel A. Galvão

Background Androgen deprivation therapy (ADT) is used extensively in the management of localized and advanced prostate cancer (PCa). 1 Although effective in delaying disease progression and enhancing survival, 1 , 2 ADT is associated with an array

Full access

Masaki Shiota

Since the work of Huggins and Hodges in the mid 1900s, primary androgen deprivation therapy (PADT) has been the backbone therapy for metastatic prostate cancer. It has recently been combined with upfront docetaxel or abiraterone. Although PADT